These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Pharmacodynamic modeling of the effect of changes in the environment on cellular lifespan and cellular response. Freise KJ; Schmidt RL; Widness JA; Veng-Pedersen P J Pharmacokinet Pharmacodyn; 2008 Oct; 35(5):527-52. PubMed ID: 18937059 [TBL] [Abstract][Full Text] [Related]
3. Interpretation of transit compartments pharmacodynamic models as lifespan based indirect response models. Krzyzanski W J Pharmacokinet Pharmacodyn; 2011 Apr; 38(2):179-204. PubMed ID: 21107661 [TBL] [Abstract][Full Text] [Related]
4. Pharmacodynamic models for agents that alter production of natural cells with various distributions of lifespans. Krzyzanski W; Woo S; Jusko WJ J Pharmacokinet Pharmacodyn; 2006 Apr; 33(2):125-66. PubMed ID: 16565883 [TBL] [Abstract][Full Text] [Related]
5. Population cell life span models for effects of drugs following indirect mechanisms of action. Perez-Ruixo JJ; Kimko HC; Chow AT; Piotrovsky V; Krzyzanski W; Jusko WJ J Pharmacokinet Pharmacodyn; 2005 Dec; 32(5-6):767-93. PubMed ID: 16328102 [TBL] [Abstract][Full Text] [Related]
6. Modeling time variant distributions of cellular lifespans: increases in circulating reticulocyte lifespans following double phlebotomies in sheep. Freise KJ; Widness JA; Schmidt RL; Veng-Pedersen P J Pharmacokinet Pharmacodyn; 2008 Jun; 35(3):285-323. PubMed ID: 18553126 [TBL] [Abstract][Full Text] [Related]
8. Basic pharmacodynamic models for agents that alter the lifespan distribution of natural cells. Krzyzanski W; Perez-Ruixo JJ; Vermeulen A J Pharmacokinet Pharmacodyn; 2008 Jun; 35(3):349-77. PubMed ID: 18551354 [TBL] [Abstract][Full Text] [Related]
9. Assessment of basic indirect pharmacodynamic response models with physiological limits. Yao Z; Krzyzanski W; Jusko WJ J Pharmacokinet Pharmacodyn; 2006 Apr; 33(2):167-93. PubMed ID: 16547797 [TBL] [Abstract][Full Text] [Related]
14. Role of dosage regimen in controlling indirect pharmacodynamic responses. Gobburu JV; Jusko WJ Adv Drug Deliv Rev; 2001 Mar; 46(1-3):45-57. PubMed ID: 11259832 [TBL] [Abstract][Full Text] [Related]
15. In vitro simulation of in vivo pharmacokinetic model with intravenous administration via flow rate modulation. Chen YC; Liang W; Hu JL; He GL; Wu XJ; Liu XF; Zhang J; Hu XQ J Pharmacokinet Pharmacodyn; 2015 Feb; 42(1):33-43. PubMed ID: 25354895 [TBL] [Abstract][Full Text] [Related]
16. Pharmacodynamic Age Structured Population Model For Cell Trafficking. Krzyzanski W; Bauer R J Pharm Sci; 2024 Jan; 113(1):257-267. PubMed ID: 37926235 [TBL] [Abstract][Full Text] [Related]
17. A paradigm shift in pharmacokinetic-pharmacodynamic (PKPD) modeling: rule of thumb for estimating free drug level in tissue compared with plasma to guide drug design. Poulin P J Pharm Sci; 2015 Jul; 104(7):2359-68. PubMed ID: 25943586 [TBL] [Abstract][Full Text] [Related]
18. Models for the red blood cell lifespan. Shrestha RP; Horowitz J; Hollot CV; Germain MJ; Widness JA; Mock DM; Veng-Pedersen P; Chait Y J Pharmacokinet Pharmacodyn; 2016 Jun; 43(3):259-74. PubMed ID: 27039311 [TBL] [Abstract][Full Text] [Related]
19. Modelling response time profiles in the absence of drug concentrations: definition and performance evaluation of the K-PD model. Jacqmin P; Snoeck E; van Schaick EA; Gieschke R; Pillai P; Steimer JL; Girard P J Pharmacokinet Pharmacodyn; 2007 Feb; 34(1):57-85. PubMed ID: 17051439 [TBL] [Abstract][Full Text] [Related]
20. Modelling cell lifespan and proliferation: is likelihood to die or to divide independent of age? Dowling MR; Milutinović D; Hodgkin PD J R Soc Interface; 2005 Dec; 2(5):517-26. PubMed ID: 16849210 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]